Format

Send to

Choose Destination
Diabet Med. 1999 Aug;16(8):692-6.

Contra-indications to metformin therapy are largely disregarded.

Author information

1
1st Department of Medicine, Klinikum Lippe-Detmold, Germany.

Abstract

AIMS:

To investigate the current metformin treatment practice and in particular to examine the consideration given to its contraindications.

METHODS:

A cross-sectional analysis of 308 consecutive Type 2 diabetic patients (mean age 66+/-11.3 years) previously treated with metformin on an outpatient basis and admitted to a German general hospital during the period from 1 January 1995 to 31 May 1998 because of acute disease or in order to optimize their diabetes management. All patients underwent a basic investigation comprising a documentation of their medical history, a physical examination, an electrocardiogram, and an extensive laboratory profile; 34% also had acute coronary angiography.

RESULTS:

On admission to hospital, 73% of the patients were found to have contra-indications, risk factors, or intercurrent illnesses necessitating discontinuation of metformin; 51% of these patients had several of these conditions. As major contra-indications to metformin, renal impairment was present in 19% of all patients, heart failure in 25%, respiratory insufficiency in 6.5%, and hepatic impairment in 1.3%. The risk factors to metformin included advanced coronary heart disease in 51%, atrial fibrillation in 9.8%, chronic alcohol abuse in 3.3%, advanced peripheral vascular disease in 2%, and pregnancy in 0.7%. As intercurrent illnesses, cerebral ischaemia occurred in 9.8% under metformin treatment and malignancies were diagnosed in 6.5%. The patients with contra-indications or requiring caution to metformin were significantly older and had previously been treated with more cardiovascular medication than those without such reservations (P<0.001).

CONCLUSIONS:

Despite the considerable risk of lactic acidosis in the majority of patients, no cases were observed.

PMID:
10477216
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center